Regeneron's blood cancer hopeful odronextamab hit with FDA partial hold across several trials

The FDA has told Regeneron to hit the brakes on its experimental blood cancer drug trial over safety concerns.

The U.S. regulator has slapped a partial clinical hold on odronextamab, a CD20xCD3 bispecific antibody in tests for B-cell non-Hodgkin lymphoma (B-NHL), after the FDA said the company has to “further reduce the incidence of Grade 3 cytokine release syndrome (CRS),” a not uncommon safety issue in certain blood cancer trials but one that can be fatal.